ISIN:DE0005313704

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Donnerstag, März 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Donnerstag, März 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24

Retrieved on: 
Freitag, Februar 9, 2024
Tax, SBU, Growth, Microsurgery, Pressure

Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%).

Key Points: 
  • Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%).
  • Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG commented on the Q1 results: “We have made a solid start to the new fiscal year.
  • The strategic business unit Microsurgery achieved revenue growth of +10.6% (adjusted for currency effects: +13.7%) to €123.9m (prior year: €112.0m).
  • The APAC [2] region recorded a slight decline in revenue of -0.9% (adjusted for currency effects: +0.4%), to €206.4m (prior fiscal year: €208.2m).

EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Samstag, Januar 13, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

Key Points: 
  • The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
  • ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

EQS-News: VISUMAX 800 mit SMILE pro Software von ZEISS erhält FDA-Zulassung in den USA

Retrieved on: 
Samstag, Januar 13, 2024
Generation, Zeiss, Femtosekundenlaser, Arbeitsablauf, Medizintechnik, Zulassung, Software, Behandlung, Kurzsichtigkeit, Astigmatismus, U.S., Druck, Administration, FDA, Zeitpunkt, Markt, Auge, SMILE, Verfahren, Menschen, Fehlsichtigkeit, Leiter, Global, Sales, Augenheilkunde, Modul (Software), Chirurgie, Technologie, Unternehmen, Patient, Ergebnis, Hause, Doktor, S., Erkenntnis, Hertz (Einheit), Sekunde, Praxis, Krankenhaus, Zentrierung, System, Drehung, Datenerfassung, Analyse, Vorhersagbarkeit, Information, Webseite

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Donnerstag, Januar 11, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Donnerstag, Januar 11, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent

Retrieved on: 
Samstag, Dezember 30, 2023
Tax, Marketing, Research, Microsurgery, SBU, Consumer, Annual, Growth, Investment, EUR, Supervisory board, Pharmaceutical industry

Carl Zeiss Meditec generated revenue of €2,089m in fiscal year 2022/23 (prior year: €1,903m), corresponding to growth of +9.8% (adjusted for currency effects: +10.1%).

Key Points: 
  • Carl Zeiss Meditec generated revenue of €2,089m in fiscal year 2022/23 (prior year: €1,903m), corresponding to growth of +9.8% (adjusted for currency effects: +10.1%).
  • Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG: “We were able to further expand our market shares in both strategic business units despite an increasingly weakening economy.
  • Revenue in the strategic business unit (SBU) Ophthalmology increased by +7.3% in fiscal year 2022/23 (adjusted for currency effects: +7.6%), to €1,576m (prior year: €1,469m).
  • Good progress in equipment deliveries during the course of the fiscal year was a major contributor to revenue growth.